1. Like an early-stage **Moderna** for breast cancer immunotherapies.

2. A developing **BioNTech**, but specializing in personalized treatments for advanced breast cancer.

3. A budding **Merck** or **Bristol Myers Squibb**, but solely dedicated to pioneering new immunotherapies for breast cancer.

• Bria-IMT: A lead immunotherapy candidate in Phase I/IIa clinical trials for breast cancer.
• Bria-OTS: A personalized immunotherapy under development for advanced breast cancer.
• BriaDx: A diagnostic test.

BriaCell Therapeutics Corp. (BCTX) is an immuno-oncology biotechnology company primarily engaged in the research and development of immunotherapies for cancer. Its lead candidate, Bria-IMT, is currently in Phase I/IIa clinical trials. As a company in the clinical development stage, BriaCell Therapeutics does not currently have commercialized products on the market and therefore does not have major commercial customers in the traditional sense.

Its primary activities involve clinical trials and research, often in collaboration with institutions like the National Cancer Institute, as mentioned in the background.

• Waisman Biomanufacturing

William V. Williams, MD, FACP President & Chief Executive Officer

Dr. Williams is a seasoned biopharmaceutical executive with over 35 years of industry and academic expertise. He has served as BriaCell's President & CEO since October 2016. Previously, Dr. Williams was Vice President of Exploratory Development at Incyte Corporation from 2005 to 2016, where he facilitated the entry of over 20 compounds into the clinic, including approvals for ruxolitinib (Jakafi) and baricitinib (Olumiant). He also served as Vice President of Clinical Pharmacology and Experimental Medicine at GlaxoSmithKline, contributing to new or supplemental drug authorizations for several oncology drugs and ibandronate (Boniva). Earlier in his career, he was Head of Rheumatology Research at the University of Pennsylvania. Dr. Williams is the named author of over 130 peer-reviewed publications, over 15 patents, and numerous Investigational New Drugs (INDs) and New Drug Applications (NDAs).

Gadi Levin, CA, MBA Chief Financial Officer & Corporate Secretary

Mr. Levin serves as the Chief Financial Officer and Corporate Secretary of BriaCell Therapeutics Corp. He was appointed as CFO in February 2016. Mr. Levin is a highly experienced accountant and businessman, with previous experience as a CFO in other companies and as VP Finance for a large hedge fund.

Giuseppe Del Priore, MD, MPH Chief Medical Officer

Dr. Del Priore is a seasoned healthcare executive with over 25 years of experience in research, drug development, and clinical trials management. He is the Chief Medical Officer at BriaCell Therapeutics Corp.

Miguel A. Lopez-Lago, PhD Chief Scientific Officer

Dr. Lopez-Lago is the Chief Scientific Officer at BriaCell Therapeutics Corp. He has extensive experience in the scientific field, with his background in research dating back to 2000.

Jamieson Bondarenko, CFA, CMT Chairman of the Board

Mr. Bondarenko is the Chairman of the Board for BriaCell Therapeutics Corp. He is an active investor and provides strategic capital markets and corporate development advice to early-stage life sciences companies through his merchant capital company, JGRNT Capital Corp. His previous roles include Principal, Managing Director, Equity Capital Markets at Eight Capital, and positions in Equity Capital Markets and Investment Banking at Dundee Capital Markets, Wellington West Capital Markets, and HSBC Securities. Mr. Bondarenko is also an angel investor who began his involvement in the startup ecosystem through BriaCell Therapeutics in 2019, and he has invested in the company.

1. Financial/Liquidity Risk and Going Concern Uncertainty: BriaCell Therapeutics is a pre-revenue, clinical-stage company with significant cash burn and consistent net losses. The company reported a net loss of approximately $26.31 million for the full year ended July 31, 2025, and used $12.88 million in cash from operating activities for the quarter ended January 31, 2025. It anticipates needing substantial additional financing, with projections of approximately $120 million through 2037 and further capital requirements for fiscal year 2026. Management has explicitly stated that continued operating losses and reliance on new financing raise "substantial doubt" about the company's ability to continue as a going concern. This ongoing need for capital, coupled with potential shareholder dilution from equity financing, poses a critical threat to its operations and long-term viability.
2. Clinical Trial Success and Regulatory Approval Risk: As an immuno-oncology biotechnology company, BriaCell's future is entirely dependent on the successful outcomes of its clinical trials and subsequent regulatory approvals. Its lead candidate, Bria-IMT, is in a pivotal Phase I/IIa clinical trial, with a Phase 3 trial underway. While the company has received positive safety recommendations from Data Safety Monitoring Boards for its Phase 3 study, the unpredictable and lengthy regulatory path, particularly with the Food and Drug Administration (FDA), means any delays or failure to achieve desired efficacy endpoints would significantly postpone potential commercial revenue and further increase its cash burn.
3. Intense Competition: The market for cancer treatments, particularly metastatic breast cancer, is highly competitive and crowded with numerous large pharmaceutical companies developing their own treatments. This intense competition poses a significant external risk, as competing therapies could emerge or gain market share, complicating BriaCell's ability to position and commercialize its treatments effectively, even if its clinical trials are successful.

BriaCell Therapeutics Corp. (BCTX) develops immunotherapies for the treatment of cancer, with key product candidates including Bria-IMT, Bria-OTS, and BriaDx. The addressable markets for these main products are as follows:

• Bria-IMT (Immunotherapy for Metastatic Breast Cancer):

  BriaCell Therapeutics estimates a potential market of $1 billion to $5 billion globally for Bria-IMT upon approval for metastatic breast cancer. More broadly, the global metastatic breast cancer treatment market was valued at $17.13 billion in 2021 and is projected to reach $41.74 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 10.4%. North America held the largest revenue share in this market in 2021.

• Bria-OTS (Personalized Immunotherapy for Advanced Breast Cancer):

  Bria-OTS targets advanced breast cancer as a personalized, off-the-shelf immunotherapy. While a specific market size for Bria-OTS is not readily available, the broader global immunotherapy market saw sales between $20 billion and $30 billion in 2017, with projections to exceed $100 billion in yearly sales by 2021. The global personalized medicine market, which includes advancements in oncology, is predicted to reach nearly $195 billion by 2024, with oncology accounting for 30% of this growth.

• BriaDx (Diagnostic Test):

  The addressable market for breast cancer diagnostics, relevant to BriaDx, shows varying estimates across different reports. The global breast cancer diagnostics market size was estimated at a range from $4.20 billion in 2023 to $28.2 billion in 2023. Projections indicate growth to approximately $6.16 billion by 2030 (at a CAGR of 6.67%), to $11.36 billion by 2033 (at a CAGR of 8.8% from 2026), to $40.71 billion by 2034 (at a CAGR of 8.13% from 2025), or to $66.9 billion by 2032 (at a CAGR of 10.2% from 2024). North America consistently held a significant share of this market, with reported shares of 45.77% in 2024 and 46.01% in 2025.

BriaCell Therapeutics (BCTX), an immuno-oncology biotechnology company, is poised for potential future revenue growth primarily driven by the advancement and commercialization of its lead immunotherapy candidates over the next 2-3 years. As a clinical-stage company, its current revenue from product sales is negligible, meaning any successful progression of its pipeline will represent significant growth.

1. Commercialization of Bria-IMT for Metastatic Breast Cancer: The primary driver of future revenue growth is the potential approval and commercialization of Bria-IMT, BriaCell's lead candidate for metastatic breast cancer. The Bria-IMT combination regimen is currently in a pivotal Phase 3 clinical study with topline data anticipated as early as the first half of 2026. Positive results from this study could lead to full regulatory approval and marketing authorization. A Biologics License Application (BLA) submission could follow in the first half of 2026 or the second half of 2027. Analysts have projected significant revenue increases for BriaCell, with one forecast estimating fiscal year 2025 revenue at $2.12 million and a substantial annual growth rate of 70.9%, likely tied to milestone payments or grants, and a forecast of $10 million in annual revenue for 2027. The market potential for Bria-IMT is estimated to be significant, potentially generating annual sales revenue of $800 million to $1.6 billion if peak market penetration is achieved.

2. Advancement and Potential Commercialization of the Bria-OTS Platform: BriaCell is also developing Bria-OTS, a personalized immunotherapy platform, which is undergoing Phase 1/2a clinical studies for breast cancer and is intended for expansion into prostate and other cancers. The company's Bria-OTS+ platform, a next-generation therapy, has shown promising preclinical data with increased tumor cell cytotoxicity in breast (Bria-BRES+) and prostate (Bria-PROS+) cancers. Data from these trials is expected to emerge over 2025 and 2026, and the company reported a sustained complete resolution of lung metastasis in a Bria-OTS patient in January 2026. Successful advancement and potential commercialization or out-licensing of the Bria-OTS platform in various cancer indications could contribute to revenue growth.

3. Strategic Partnerships and Licensing Agreements: As a clinical-stage biotechnology company, BriaCell's future revenue growth will also be driven by strategic partnerships and licensing agreements. These collaborations could provide upfront payments, milestone payments based on development and regulatory achievements, and future royalties on sales. The company already has a cooperative research and development agreement with the National Cancer Institute for Bria-OTS. Analyst forecasts for future revenue, particularly in the near term while product sales are non-existent, are likely to include income generated from such non-commercial sources like grants and milestone payments from collaborations.

Share Repurchases

• On September 9, 2021, BriaCell Therapeutics authorized a share repurchase program to acquire up to 1,341,515 common shares and up to 411,962 publicly traded warrants (BCTXW) over a 12-month period. This represented 10% of the company's public float at the time.

Share Issuance

• In January 2026, the company completed a public offering of 5.37 million units, each comprising one common share and one warrant, at a price of $5.59 per unit, generating approximately $30 million in gross proceeds. Net equity financing proceeds for the half-year ending January 31, 2026, were $27.9 million.
• In July 2025, BriaCell priced a public offering of 12,000,000 units, consisting of common shares (or pre-funded warrants) and warrants, at $1.25 per unit, resulting in gross proceeds of $15 million.
• In December 2024, BriaCell closed an underwritten public offering of 7,400,000 common shares and associated warrants at a combined price of $0.75 per share and warrant, raising $5.55 million in gross proceeds.

Inbound Investments

• BriaCell Therapeutics received a non-dilutive $2 million grant from the U.S. National Cancer Institute (NCI) to advance its Bria-PROS+ program towards clinical stages. This funding is intended to assist in manufacturing clinical supply and support Phase 1/2a development for metastatic prostate cancer, as well as accelerate the existing Bria-OTS immunotherapy program.

Capital Expenditures

• As a pre-revenue clinical-stage company, BriaCell's capital expenditures are primarily driven by research and development (R&D) activities. For the fiscal year ended July 31, 2025, the company reported $20.81 million in R&D costs, contributing to a net loss of approximately $26.31 million.
• For the six months ended January 31, 2026, research, development, and clinical trial expenses increased to $12.7 million from $9.4 million in the prior year, mainly to support the pivotal Bria-IMT™ Phase 3 metastatic breast cancer trial and the Bria-OTS™ Phase 1/2a program.
• The company anticipates requiring approximately $120 million in additional financing through 2037, with further capital requirements projected for fiscal year 2026, to fund the advancement of its clinical programs, especially the Bria-IMT™ Phase 3 study.